Duncan Pamela W, Bushnell Cheryl D, Rosamond Wayne D, Jones Berkeley Sara B, Gesell Sabina B, D'Agostino Ralph B, Ambrosius Walter T, Barton-Percival Blair, Bettger Janet Prvu, Coleman Sylvia W, Cummings Doyle M, Freburger Janet K, Halladay Jacqueline, Johnson Anna M, Kucharska-Newton Anna M, Lundy-Lamm Gladys, Lutz Barbara J, Mettam Laurie H, Pastva Amy M, Sissine Mysha E, Vetter Betsy
Department of Neurology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC, 27157, USA.
Department of Epidemiology, University of North Carolina at Chapel Hill, Gillings School of Global Public Health, 135 Dauer Drive, Chapel Hill, 27599, USA.
BMC Neurol. 2017 Jul 17;17(1):133. doi: 10.1186/s12883-017-0907-1.
Patients discharged home after stroke face significant challenges managing residual neurological deficits, secondary prevention, and pre-existing chronic conditions. Post-discharge care is often fragmented leading to increased healthcare costs, readmissions, and sub-optimal utilization of rehabilitation and community services. The COMprehensive Post-Acute Stroke Services (COMPASS) Study is an ongoing cluster-randomized pragmatic trial to assess the effectiveness of a comprehensive, evidence-based, post-acute care model on patient-centered outcomes.
Forty-one hospitals in North Carolina were randomized (as 40 units) to either implement the COMPASS care model or continue their usual care. The recruitment goal is 6000 patients (3000 per arm). Hospital staff ascertain and enroll patients discharged home with a clinical diagnosis of stroke or transient ischemic attack. Patients discharged from intervention hospitals receive 2-day telephone follow-up; a comprehensive clinic visit within 2 weeks that includes a neurological evaluation, assessments of social and functional determinants of health, and an individualized COMPASS Care Plan™ integrated with a community-specific resource database; and additional follow-up calls at 30 and 60 days post-stroke discharge. This model is consistent with the Centers for Medicare and Medicaid Services transitional care management services provided by physicians or advanced practice providers with support from a nurse to conduct patient assessments and coordinate follow-up services. Patients discharged from usual care hospitals represent the control group and receive the standard of care in place at that hospital. Patient-centered outcomes are collected from telephone surveys administered at 90 days. The primary endpoint is patient-reported functional status as measured by the Stroke Impact Scale 16. Secondary outcomes are: caregiver strain, all-cause readmissions, mortality, healthcare utilization, and medication adherence. The study engages patients, caregivers, and other stakeholders (including policymakers, advocacy groups, payers, and local community coalitions) to advise and support the design, implementation, and sustainability of the COMPASS care model.
Given the high societal and economic burden of stroke, identifying a care model to improve recovery, independence, and quality of life is critical for stroke survivors and their caregivers. The pragmatic trial design provides a real-world assessment of the COMPASS care model effectiveness and will facilitate rapid implementation into clinical practice if successful.
Clinicaltrials.gov: NCT02588664 ; October 23, 2015.
中风后出院回家的患者在管理残留神经功能缺损、二级预防和既存慢性病方面面临重大挑战。出院后护理往往零散,导致医疗费用增加、再入院以及康复和社区服务利用不足。综合急性中风后服务(COMPASS)研究是一项正在进行的整群随机实用试验,旨在评估一种以患者为中心的综合循证急性后期护理模式的有效性。
北卡罗来纳州的41家医院(作为40个单位)被随机分组,要么实施COMPASS护理模式,要么继续其常规护理。招募目标是6000名患者(每组3000名)。医院工作人员确定并招募临床诊断为中风或短暂性脑缺血发作后出院回家的患者。干预医院出院的患者接受为期2天的电话随访;在2周内进行一次全面门诊,包括神经学评估、健康的社会和功能决定因素评估,以及与社区特定资源数据库整合的个性化COMPASS护理计划™;中风出院后30天和60天进行额外随访电话。该模式与医疗保险和医疗补助服务中心由医生或高级执业提供者在护士支持下提供的过渡性护理管理服务一致,以进行患者评估和协调随访服务。常规护理医院出院的患者代表对照组,接受该医院现有的标准护理。以患者为中心的结局通过90天的电话调查收集。主要终点是通过中风影响量表16测量的患者报告的功能状态。次要结局包括:照顾者负担、全因再入院、死亡率、医疗利用和药物依从性。该研究让患者、照顾者和其他利益相关者(包括政策制定者、倡导团体、支付方和当地社区联盟)参与,为COMPASS护理模式的设计、实施和可持续性提供建议和支持。
鉴于中风的社会和经济负担沉重,确定一种改善康复、独立性和生活质量的护理模式对中风幸存者及其照顾者至关重要。实用试验设计对COMPASS护理模式的有效性进行了现实世界评估,如果成功,将有助于迅速在临床实践中实施。
Clinicaltrials.gov:NCT02588664;2015年10月23日。